Cargando…

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies

Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least another one directed against an activating receptor in immune effector cells: CD3 for recruitment of T cells and CD16a for NK cells. The first T cell engager (the anti-CD19 blinatumom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tapia-Galisteo, Antonio, Álvarez-Vallina, Luis, Sanz, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373336/ https://www.ncbi.nlm.nih.gov/pubmed/37501154 http://dx.doi.org/10.1186/s13045-023-01482-w

Ejemplares similares

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022)

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins
por: Debelec-Butuner, Bilge, et al.
Publicado: (2022)

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
por: Pekar, Lukas, et al.
Publicado: (2020)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

Therapeutic Advances in Immunotherapies for Hematological Malignancies
por: Nogami, Ayako, et al.
Publicado: (2022)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
por: Abrams, R. E., et al.
Publicado: (2022)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

Immunotherapy in hematologic malignancies: past, present, and future
por: Im, Annie, et al.
Publicado: (2017)

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
por: Wang, Bo, et al.
Publicado: (2022)

Engineered mRNA and the Rise of Next-Generation Antibodies
por: Sanz, Laura, et al.
Publicado: (2021)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Immune Regulation by Pericytes: Modulating Innate and Adaptive Immunity
por: Navarro, Rocío, et al.
Publicado: (2016)

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
por: Ye, Baixin, et al.
Publicado: (2017)

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
por: Ravirala, Divya, et al.
Publicado: (2021)

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
por: Tang, Lu, et al.
Publicado: (2023)

Correction for Khan et al., “Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry”
por: Khan, Salar N., et al.
Publicado: (2019)

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Editorial: Immunotherapy for hematological malignancies in children
por: Zhou, Yusi, et al.
Publicado: (2023)

Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
por: Allegra, Alessandro, et al.
Publicado: (2021)

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
por: Xu, Zhengli, et al.
Publicado: (2021)

The landscape overview of CD47-based immunotherapy for hematological malignancies
por: Yang, Hua, et al.
Publicado: (2023)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
por: Guo, Zong Sheng, et al.
Publicado: (2020)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
por: Bogen, Jan P., et al.
Publicado: (2021)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
por: Warmuth, Stefan, et al.
Publicado: (2021)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
por: Innao, Vanessa, et al.
Publicado: (2020)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era
por: Miazek-Zapala, Nina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m4oj50cvumqghk5fphqejkfl79